A detailed history of Personal Cfo Solutions, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Personal Cfo Solutions, LLC holds 61,731 shares of BCRX stock, worth $462,365. This represents 0.07% of its overall portfolio holdings.

Number of Shares
61,731
Previous 61,731 -0.0%
Holding current value
$462,365
Previous $381,000 23.1%
% of portfolio
0.07%
Previous 0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$4.13 - $6.79 $20,650 - $33,950
-5,000 Reduced 7.49%
61,731 $381,000
Q1 2024

May 13, 2024

BUY
$4.89 - $7.65 $2,092 - $3,274
428 Added 0.65%
66,731 $338,000
Q4 2023

Feb 13, 2024

SELL
$4.98 - $6.77 $2,255 - $3,066
-453 Reduced 0.68%
66,303 $397,000
Q2 2023

Aug 10, 2023

SELL
$6.96 - $8.81 $6,960 - $8,810
-1,000 Reduced 1.48%
66,756 $469,000
Q1 2023

May 09, 2023

BUY
$7.94 - $11.84 $2,906 - $4,333
366 Added 0.54%
67,756 $565,000
Q3 2022

Nov 01, 2022

BUY
$10.79 - $14.81 $3,258 - $4,472
302 Added 0.45%
67,390 $849,000
Q2 2022

Aug 05, 2022

SELL
$7.89 - $17.88 $332,169 - $752,748
-42,100 Reduced 38.56%
67,088 $710,000
Q3 2021

Nov 18, 2021

SELL
$14.21 - $17.65 $35,382 - $43,948
-2,490 Reduced 2.23%
109,188 $1.57 Million
Q2 2021

Jul 22, 2021

SELL
$9.5 - $17.24 $95,000 - $172,399
-10,000 Reduced 8.22%
111,678 $1.77 Million
Q1 2021

Apr 21, 2021

BUY
$7.37 - $13.61 $121,605 - $224,565
16,500 Added 15.69%
121,678 $1.24 Million
Q4 2020

Feb 09, 2021

BUY
$3.37 - $8.61 $47,180 - $120,539
14,000 Added 15.35%
105,178 $783,000
Q3 2020

Nov 02, 2020

BUY
$3.43 - $5.53 $29,155 - $47,005
8,500 Added 10.28%
91,178 $0
Q2 2020

Aug 03, 2020

SELL
$1.9 - $5.61 $8,360 - $24,684
-4,400 Reduced 5.05%
82,678 $394,000
Q1 2020

Apr 30, 2020

BUY
$1.6 - $4.11 $88,124 - $226,370
55,078 Added 172.12%
87,078 $174,000
Q4 2019

Feb 13, 2020

BUY
$1.59 - $3.45 $50,880 - $110,400
32,000 New
32,000 $110,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Personal Cfo Solutions, LLC Portfolio

Follow Personal Cfo Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Personal Cfo Solutions, LLC with notifications on news.